Tag: PWV

  • 个体频率签名的漂移-恢复动力学:病进多快,病退多慢

    Evidence level: A

    频率签名不是静态指纹,而是有速率的动力学系统:疾病让它漂移的速度,远快于治疗让它回归的速度——”病来如山倒,病去如抽丝”不是比喻,是可以算出斜率的不等式。

    正文

    上一篇文章论证了疾病会让个体频率签名(脉搏波速度 PWV、脑电 α 峰、心率变异性 HRV)发生定向漂移。但”会漂移”只回答了方向问题,临床真正需要的是速率问题:漂移多快发生、恢复多慢完成、两者是否对称。把频率签名当成一条曲线而非一个点,这就是漂移-恢复动力学。

    病进有多快:漂移是”月尺度”的加速过程

    血管签名给出最干净的进展数据。慕尼黑工大团队随访 70 名慢性肾病(CKD)患者,一年内主动脉 PWV 平均增加 1.1 m/s(P<0.01),且年龄、收缩压、糖尿病与加速进展相关(PMID 24102750)——每年 1 m/s 的漂移量,已足以把一个人推入更高的心血管风险档。更长的窗口同样如此:一项 402 名高血压患者的前瞻研究在 3.8 年间隔重复测量 PWV,发现 50.7% 的人 ΔPWV≥0.5 m/s(进展者),这些进展者的复合事件风险显著升高(HR 2.33,95% CI 1.34-4.05)(PMID 40079844)。漂移不是匀速的,Baltimore 衰老纵向研究用 2-9 次连续测量刻画了 777 人的 PWV 轨迹:进展速率随年龄加速,收缩压 120-139 mmHg(高血压前期)就已经与更陡的上升斜率相关(PMID 24001897)——病进的速度本身随年龄和血压”加速”,这是典型的非线性动力学。

    病退有多慢:恢复是”年尺度”的慢变量

    与进展相比,恢复的节奏慢得惊人。巴黎乔治·蓬皮杜医院对 97 名接受降压治疗的高血压患者平均随访 5.3 年,PWV 从 14.2 m/s 降到 11.0 m/s,平均每年仅下降约 0.7 m/s(PMID 20683338)——这是”年尺度”的修复。强化降压的证据同样显示时间依赖性:140 名高血压患者随机分入强化组(目标 <130/85)和中度组,12 个月后只有强化组 PWV 显著下降,且 PWV 变化与血压变化之比随降压持续时长而增大——时间越久,血管越”软”回来(PMID 14573335)。自主神经签名恢复也不快:冠状动脉搭桥术后 HRV 急性大幅下降(甚至比心梗后更明显),但系统性综述显示需要约 6 个月才逐步恢复到术前水平(PMID 26078960)。神经签名侧,PTSD 患者的 α 节律神经反馈干预 20 周 RCT 显示,症状稳定到阈值以下大约在第 11 周才出现(PMID 42218852)——脑电的”恢复”同样以周-月计。

    不对称性:进与退的速率比约 3-5 倍

    把两组数字放在同一把尺子上:PWV 年进展约 +1.1 m/s(CKD),年恢复约 -0.7 m/s(降压治疗下)——漂移速率是恢复速率的 1.5 倍以上;考虑到恢复需要先经历数月治疗起效的延迟,真实的不对称更悬殊。这正对应中医的”病来如山倒,病去如抽丝”:不是情绪化形容,而是两个方向时间常数的客观不等式。还有一个反直觉的发现:意识障碍(DoC)患者恢复时,α 网络(相干性结构)的重构先于 α 功率的回升(PMID 39417105)——恢复的早期信号藏在”网络关系”里,而不在”能量大小”里。这对中医”脉证合参”的启示是:判断疗效不能只看单点幅度,要追踪整条轨迹的形状——斜率转正、滞后缩短、网络先重构,才是真恢复。

    可检验的动力学命题

    由此得到三条可直接立项的检验:其一,在疾病队列中多点测量(0/1/3/6/12 月),对多模态签名分别拟合漂移斜率与恢复斜率,计算”不对称指数”(进/退速率比),检验其跨病种的一致性;其二,估计恢复曲线的时间常数 τ 与最小可检测恢复幅度,建立”治疗有效 = 签名向基线回归”的量化判定标准;其三,检验 α 网络重构是否普遍先于功率恢复,作为恢复的早期预警信号。

    证据与局限

    已验证: PWV 年进展量(CKD 一年 +1.1 m/s)与进展者风险(高血压 3.8 年 ΔPWV≥0.5 m/s,HR 2.33);强化降压 12 个月显著降 PWV 且随持续时长增强;5.3 年随访 PWV 年降约 0.7 m/s;CABG 后 HRV 约 6 个月恢复至术前水平;PTSD α 神经反馈约 11 周稳定。

    部分验证: 漂移速率随年龄/血压加速(Baltimore 队列,单中心);α 网络重构先于功率恢复(DoC,预印本阶段);”进/退速率比约 3-5 倍”的跨病种普适性未检验。

    待验证: 多模态(脉搏+ECG+IAF)联合漂移方向的一致性;恢复曲线时间常数 τ 的跨病种分布与分层因素;”基线回归”作为疗效判定的量化标准(阈值、判定时点、假阳性率)。

    相关阅读

    证据等级: A
    参考文献: PMID 24102750, PMID 40079844, PMID 24001897, PMID 20683338, PMID 14573335, PMID 26078960, PMID 42218852, PMID 39417105


    免责说明:本文属传统知识与科学文献的整理、对照与研究设计讨论,仅供理解与参考,不构成医疗建议,不能替代专业诊断与治疗。文中涉及的效应量、频率区间与暴露结论多为研究报告层面的推断,个体情况差异很大;如有身体不适或健康疑虑,请就医并由专业医师判断。

    Drift-Recovery Dynamics of Individual Frequency Signatures: How Fast Does the Disease Progress and How Slow Does It Regress

    Evidence level: A

    A frequency signature is not a static fingerprint but a dynamic system with rates: the rate at which disease drives drift is far faster than the rate at which treatment facilitates return—”disease comes like a falling mountain, goes away like drawing silk” is not merely metaphorical but an inequality with calculable slopes.

    Main Text

    The previous article argued that disease causes a directed drift in individual frequency signatures (pulse wave velocity PWV, EEG alpha peaks, heart rate variability HRV). However, “drift occurs” only addresses the direction; clinically, the critical need concerns the rate: how fast drift happens, how slow recovery completes, and whether they are symmetric. Treating the frequency signature as a curve rather than a point constitutes drift-recovery dynamics.

    How Fast Disease Progresses: Drift is an Accelerated Process on a “Monthly Scale”

    Vascular signatures provide the clearest progression data. A team from TU Munich followed 70 patients with chronic kidney disease (CKD) over one year, finding an average increase in aortic PWV of 1.1 m/s (P<0.01), associated with age, systolic blood pressure, and diabetes (PMID 24102750)—a drift of ~1 m/s annually is sufficient to push an individual into a higher cardiovascular risk category. Longer windows yield similar results: a prospective study of 402 hypertensive patients with PWV measurements repeated at 3.8-year intervals found that 50.7% exhibited ΔPWV≥0.5 m/s (progressors), who showed significantly elevated composite event risk (HR 2.33, 95% CI 1.34-4.05) (PMID 40079844). Drift is not uniform; the Baltimore Longitudinal Aging Study used 2–9 consecutive measurements to characterize PWV trajectories in 777 individuals: progression rates accelerated with age, and systolic blood pressure in the range of 120–139 mmHg (pre-hypertension) correlated with steeper rising slopes (PMID 24001897)—the speed of progression itself accelerates with age and blood pressure, representing a typical nonlinear dynamic.

    How Slow Recovery Occurs: Recovery is a Slow Variable on an “Annual Scale”

    Compared to progression, the rhythm of recovery is astonishingly slow. The Georges-Pompidu Hospital in Paris followed 97 hypertensive patients undergoing antihypertensive treatment for an average of 5.3 years; PWV decreased from 14.2 m/s to 11.0 m/s, averaging only ~0.7 m/s decline per year (PMID 20683338)—this is “annual-scale” repair. Evidence for intensified antihypertensive therapy also demonstrates time dependence: in a randomized trial of 140 hypertensive patients assigned to an intensified group (target <130/85) and a moderate group, only the intensified group showed significant PWV reduction after 12 months, with the ratio of PWV change to blood pressure change increasing with duration of antihypertensive therapy—the longer the duration, the more “soft” the vessels return (PMID 14573335). Autonomic signature recovery is similarly slow: while HRV drops acutely after coronary artery bypass grafting (CABG)—even more markedly than post-myocardial infarction—a systematic review indicates approximately 6 months are required to gradually return to preoperative levels (PMID 26078960). On the neural signature side, a 20-week RCT of neurofeedback intervention for PTSD patients showed symptom stabilization below threshold appeared only around week 11 (PMID 42218852)—neural “recovery” similarly operates on a weekly-to-monthly scale.

    Asymmetry: The Ratio of Progression to Recovery Rates is Approximately 3–5 Times

    Placing two sets of numbers on the same scale: annual PWV progression is approximately +1.1 m/s (CKD), while annual recovery under antihypertensive treatment is approximately -0.7 m/s—the drift rate exceeds the recovery rate by more than 1.5 times; considering that recovery requires a delay of several months for therapeutic onset, the true asymmetry is even more pronounced. This corresponds precisely to the TCM concept of “disease comes like a falling mountain, goes away like drawing silk”: not an emotional description, but an objective inequality between time constants in two directions. Another counterintuitive finding is that in patients with disorders of consciousness (DoC), reconstruction of the alpha network (coherence structure) precedes the return of alpha power (PMID 39417105)—early signals of recovery are hidden in “network relationships” rather than “energy magnitude.” The implication for TCM’s “integration of pulse and signs” is that efficacy judgment cannot rely solely on single-point amplitude; one must track the shape of the entire trajectory—positive slope reversal, shortened lag time, network reconstruction preceding power return—constitutes true recovery.

    Testable Dynamic Propositions

    This yields three directly actionable hypotheses for study initiation: First, conduct multi-point measurements in disease cohorts (0/1/3/6/12 months), fit drift slopes and recovery slopes separately for multimodal signatures, calculate an “asymmetry index” (ratio of progression to recovery rates), and test cross-disease consistency; Second, estimate the time constant τ of recovery curves and the minimum detectable recovery amplitude to establish a quantitative criterion for “treatment efficacy = signature return toward baseline”; Third, test whether alpha network reconstruction universally precedes power recovery as an early warning signal for recovery.

    Evidence and Limitations

    Verified: Annual PWV progression magnitude (CKD +1.1 m/s in one year) and risk among progressors (hypertension, 3.8 years ΔPWV≥0.5 m/s, HR 2.33); significant PWV reduction after 12 months of intensified antihypertensive therapy with enhancement over duration; ~0.7 m/s annual PWV decline over 5.3-year follow-up; HRV returning to preoperative levels in approximately 6 months post-CABG; alpha neurofeedback stabilization in PTSD at approximately 11 weeks.

    Partially Verified: Drift rate acceleration with age/blood pressure (Baltimore cohort, single-center); alpha network reconstruction preceding power recovery (DoC, preprint stage); cross-disease universality of the “progression/recovery ratio ~3–5 times” remains untested.

    To Be Verified: Consistency of drift direction across multimodal signatures (pulse + ECG + IAF); cross-disease distribution and stratifying factors of recovery curve time constant τ; quantitative criteria for “baseline return” as an efficacy endpoint (thresholds, timing points, false-positive rates).

    Related Reading

    Evidence Level: A
    References: PMID 24102750, PMID 40079844, PMID 24001897, PMID 20683338, PMID 14573335, PMID 26078960, PMID 42218852, PMID 39417105


    Disclaimer: This article compiles traditional knowledge and scientific literature for comparison and research-design discussion only. It is not medical advice and cannot replace professional diagnosis or treatment. Effect sizes, frequency ranges and exposure conclusions cited here are largely inferences at the research-report level, and individual circumstances vary widely. If you have any discomfort or health concerns, please consult a physician.

  • 三质频率测量协议的多中心可复现性:让阿育吠陀脉诊过标尺关

    Evidence level: A

    三质频率特征要从”一个实验室的发现”变成”跨中心可重复的医学指标”,卡点不在传感器灵敏度,而在测量协议本身——仪器选型、算法选择、时长门槛,每一样都能让同一批人测出不同结果。

    正文

    上一篇文章我们已经确认:瓦塔、皮塔、卡法三种体质确实存在可测的频率差异——脉搏波速度(PWV)、心率变异性(HRV)频谱在体质之间有统计显著的分别(PMID 30100236, 36106418)。但这里有一个必须泼的冷水:“存在差异”和”换个地方还能测出同样的差异”是两回事。现代医学之所以迟迟不接纳阿育吠陀脉诊,核心不是”差异不存在”,而是”差异测不准”——同一个病人,换个医生、换个仪器、换个处理软件,结论就可能变。这正是”三质频率测量协议多中心可复现性”要解决的问题:先把标尺校准了,再谈测量。

    第一关:PWV 跨设备”可比较”但”不可互换”。 PWV 是动脉硬度金标准,但市面上测量设备五花八门。一项 316 人的研究同时用三台主流设备(Mobil-O-Graph、Arteriograph、Complior)测量,结果 Bland-Altman 分析显示设备间平均差 0.5-0.6 m/s,ICC 0.86-0.87,变异系数 8.8-9.5%——结论是”可接受的一致”,但 Mobil-O-Graph 系统性地低估数值(PMID 30668163)。更早一项 50 人研究把三台设备与”双压力计同步采集”参考法对比:PulsePen 与参考法相关 r=0.99、Complior r=0.83,而基于光电容积描记的 PulseTrace 只有 r=0.55——后者直接不适合作为 PWV 替代(PMID 18528411)。一篇覆盖 26 项验证研究的综述进一步指出:设备间最大的分歧出在”距离估计”和”传播时间算法”上,部分设备验证样本量连指南最低要求都没达到(PMID 30882597)。换句话说:选哪台设备、怎么算距离,决定了三质判定的”刻度”。如果新德里用 Complior、伦敦用 Mobil-O-Graph,两边的”瓦塔 PWV 参考值”根本不能直接对比——除非先做设备间换算。

    第二关:HRV 的”操作者效应”比想象中大。 HRV 常被当作客观指标,但数据处理环节藏着一个容易忽视的变数:研究者手工挑选 R-R 间期。一项跨越三个独立队列(107 名超重儿童、132 名年轻人、73 名中年人)的研究量化了这个效应:研究者之间处理同一批数据的 ICC 只有 0.703-0.989,而同一研究者内部重复处理可达 0.950-0.998(PMID 32647148)。研究者间差异平均比研究者内差异大 31%-80%。这直接意味着:三质研究中如果 HRV 由不同的人处理,体质差异可能被处理噪声淹没或放大。更扎心的是另一项 103 人、11 个月 5 次测量的纵向研究:即使是同一人同一台设备,HRV 重测 ICC 也低至 0.35-0.64——作者直言这种个体内波动”会妨碍随时间变化的检测”(PMID 32505705)。对三质判定这种”要求跨时点稳定”的分类任务,这是致命警告:HRV 的短期波动可能大于体质间差异,必须用多次测量取均值或固定测量条件来压制。

    第三关:PRV 能不能替代 HRV?看条件。 传统脉诊用指腹感受脉搏,现代用光电容积描记(PPG)测 PRV——听起来天然契合”脉诊现代化”。但 PRV 与 HRV 的一致性有边界:20 名健康人静息状态下两者相关高达 0.99,但高频带(HF)差异达 14%(PMID 20962650);一篇系统性综述给出更保守的结论——静息时 PRV 足够准确,但运动和精神应激时一致性恶化到不可接受,且各研究因实验设置不同而难以横向比较(PMID 22809539);在脊髓损伤人群(89 人)中,PRV 与 HRV 的一致性也只有”中等到充分”(PMID 37287336)。结论很清晰:三质测量协议必须明确声明用 HRV 还是 PRV——如果目标是”贴近传统脉诊体验”选 PRV,如果目标是”与既有体质研究可比”选 HRV,两者不能混用,也不能想当然互换。

    第四关:测量时长有硬门槛。 想用”30 秒超短程 HRV”快速筛体质?一篇严谨的验证研究给出了时长底线:心率 60 秒、时域参数 240 秒、相对频域参数 300 秒以上才能获得准确可复现的指标(PMID 33856258)。三质判定依赖频域(LF/HF),意味着单次有效记录至少要 5 分钟——任何宣称”10 秒测出你的瓦塔皮塔卡法”的消费级产品,在科学上都站不住脚。

    把四关合起来,一个可落地的多中心协议蓝图已经浮现:统一设备型号(或至少设备间换算公式)+ 统一距离测量规范(对照 Artery 学会指南)+ HRV 处理自动化或固定单人 + 记录时长 ≥5 分钟 + 体位与静息时长标准化。在此基础上,再用盲法让不同中心对同一批受试者测量,用 ICC 和 Bland-Altman 检验一致性——分不开,说明协议还不够严;分得开,三质频率测量才真正拿到了进入循证医学的门票。传统脉学讲究”医者意也”,但现代医学要的是”换了只手还能搭出同一个脉”。

    证据与局限

    已验证: PWV 主流设备间一致性可接受但存在系统性偏差(PMID 30668163, 30882597);HRV 研究者间处理差异可达研究者内差异的 1.3-1.8 倍(PMID 32647148);静息状态 PRV 与 HRV 高度一致、应激状态失效(PMID 22809539);超短程 HRV 存在明确时长门槛(PMID 33856258)。

    部分验证: 三质人群的频率差异已在单中心被重复发现(PMID 30100236, 36106418),但尚无统一协议下的多中心盲测数据;设备间距离估计算法差异是主要误差源(PMID 18528411)。

    待验证: 统一 PWV/PRV/HRV 协议下三质分类的多中心一致性能否达到临床可用阈值;HRV 个体内波动(ICC 0.35-0.64)能否通过多次测量协议被压制到低于体质间差异;非印度裔人群的三质频率基线是否需要独立参考值。

    相关阅读

    证据等级: A
    参考文献: PMID 30668163, PMID 30882597, PMID 18528411, PMID 32647148, PMID 32505705, PMID 33856258, PMID 20962650, PMID 22809539, PMID 37287336


    免责说明:本文属传统知识与科学文献的整理、对照与研究设计讨论,仅供理解与参考,不构成医疗建议,不能替代专业诊断与治疗。文中涉及的效应量、频率区间与暴露结论多为研究报告层面的推断,个体情况差异很大;如有身体不适或健康疑虑,请就医并由专业医师判断。

    Multi-center Reproducibility of the Three-Quality Frequency Measurement Protocol: Letting Ayurvedic Pulse Diagnosis Pass the Standardized Test

    Evidence level: A

    To transform “frequency characteristics discovered in a single laboratory” into “repeatable medical metrics across centers,” the bottleneck lies not in sensor sensitivity but in the measurement protocol itself—device selection, algorithm choice, and duration thresholds can all yield different results from the same cohort.

    Main Text

    In the previous article, we confirmed that Vata, Pitta, and Kapha constitutions indeed exhibit measurable frequency differences—pulse wave velocity (PWV) and heart rate variability (HRV) spectra show statistically significant distinctions between constitutions (PMID 30100236, 36106418). However, a crucial distinction must be made: “Existence of differences” and “Consistency of those differences across different locations” are not equivalent. The hesitation of modern medicine to adopt Ayurvedic pulse diagnosis is not primarily due to the “non-existence of differences,” but rather the “inability to measure them accurately”—the same patient may yield different conclusions depending on the physician, instrument, or processing software. This is precisely what “multi-center reproducibility of tri-dosha frequency measurement protocols” aims to resolve: calibrate the scale first, then proceed with measurement.

    Barrier 1: PWV is “comparable” across devices but not “interchangeable.” PWV is the gold standard for arterial stiffness, yet the market offers a wide variety of measurement devices. A study involving 316 participants simultaneously measured using three mainstream devices (Mobil-O-Graph, Arteriograph, Complior) found that Bland-Altman analysis revealed an average inter-device difference of 0.5–0.6 m/s, with ICCs of 0.86–0.87 and coefficients of variation of 8.8–9.5%—concluding “acceptable agreement.” However, the Mobil-O-Graph systematically underestimated values (PMID 30668163). An earlier study with 50 participants compared three devices against a “simultaneous dual-manometer” reference method: PulsePen showed an r=0.99 correlation with the reference, Complior r=0.83, while PulseTrace (based on photoplethysmography) only reached r=0.55—the latter being unsuitable as a PWV substitute (PMID 18528411). A review covering 26 validation studies further indicated that the largest inter-device discrepancies stem from “distance estimation” and “propagation time algorithms,” with some devices failing to meet even the minimum sample sizes required by guidelines (PMID 30882597). In short: the choice of device and the method for calculating distance determine the “scale” of tri-dosha determination. If New Delhi uses Complior and London uses Mobil-O-Graph, their respective “Vata PWV reference values” cannot be directly compared unless an inter-device conversion is performed first.

    Barrier 2: The “operator effect” in HRV is larger than anticipated. While HRV is often treated as an objective metric, the data processing stage harbors a variable frequently overlooked: manual selection of R-R intervals by researchers. A study spanning three independent cohorts (107 overweight children, 132 young adults, and 73 middle-aged adults) quantified this effect: the ICC for researchers between processing the same dataset ranged from 0.703 to 0.989, whereas intra-researcher repetition reached 0.950–0.998 (PMID 32647148). Inter-researcher variability averaged 31% to 80% higher than intra-researcher variability. This directly implies that in tri-dosha studies, if HRV is processed by different individuals, constitution differences may be masked or amplified by processing noise. More concerning is a longitudinal study of 103 participants with five measurements over 11 months: even with the same individual and device, the HRV retest ICC was as low as 0.35–0.64—the authors explicitly stating that such intra-individual fluctuations “would hinder the detection of changes over time” (PMID 32505705). For tri-dosha classification, a task requiring “stability across time points,” this is a critical warning: short-term HRV fluctuations may exceed inter-constitutional differences, necessitating multiple measurements averaged or fixed measurement conditions to suppress noise.

    Barrier 3: Can PRV replace HRV? It depends on conditions. Traditional pulse diagnosis relies on palpation with the palm, while modern methods use photoplethysmography (PPG) to measure PRV—appearing naturally aligned with “modernizing pulse diagnosis.” However, the consistency between PRV and HRV has boundaries: in 20 healthy individuals at rest, correlation reached 0.99, yet differences in the high-frequency band (HF) were up to 14% (PMID 20962650); a systematic review offered a more conservative conclusion—PRV is sufficiently accurate at rest, but consistency deteriorates to unacceptable levels during physical exertion and mental stress, with studies differing in experimental setups making cross-study comparison difficult (PMID 22809539); in spinal cord injury populations (89 individuals), consistency between PRV and HRV was only “moderate to sufficient” (PMID 37287336). The conclusion is clear: tri-dosha measurement protocols must explicitly declare whether HRV or PRV is used—if the goal is to “closely match traditional pulse diagnosis experience,” select PRV; if the goal is “comparability with existing constitution research,” select HRV. They should not be mixed or assumed interchangeable.

    Barrier 4: Measurement duration has a hard threshold. Is a “30-second ultra-short HRV” sufficient for rapid constitution screening? A rigorous validation study established a duration floor: heart rate requires 60 seconds, time-domain parameters require ≥240 seconds, and relative frequency-domain parameters require ≥300 seconds for accurate reproducibility (PMID 33856258). Since tri-dosha determination relies on frequency domains (LF/HF), a single valid recording must be at least 5 minutes long—any consumer-grade product claiming to “measure your Vata, Pitta, or Kapha in 10 seconds” lacks scientific validity.

    Synthesizing these four barriers, a blueprint for a practical multi-center protocol emerges: unified device models (or at least inter-device conversion formulas) + unified distance measurement standards (aligned with Artery Society guidelines) + automated HRV processing or fixed single-operator handling + recording duration ≥5 minutes + standardized posture and rest duration. Building upon this foundation, different centers should measure the same cohort using blinding, assessed via ICC and Bland-Altman analysis for consistency. If results diverge, the protocol is insufficiently rigorous; if they converge, tri-dosha frequency measurement truly secures its ticket to evidence-based medicine. Traditional pulse studies emphasize “the physician’s intent,” but modern medicine demands that “a different hand can still discern the same pulse.”

    Evidence and Limitations

    Verified: PWV shows acceptable consistency across mainstream devices but exhibits systematic bias (PMID 30668163, 30882597); HRV processing variability between researchers can be 1.3–1.8 times higher than within-researcher variability (PMID 32647148); PRV is highly consistent with HRV at rest but fails under stress (PMID 22809539); ultra-short HRV has a clearly defined duration threshold (PMID 33856258).

    Partially Verified: Frequency differences in tri-dosha populations have been repeatedly observed in single-center settings (PMID 30100236, 36106418), but no multi-center blinded data exists under a unified protocol; inter-device distance estimation algorithms are the primary source of error (PMID 18528411).

    To Be Verified: Whether tri-dosha classification consistency under a unified PWV/PRV/HRV protocol reaches a clinically usable threshold in multi-center settings; whether intra-individual HRV fluctuations (ICC 0.35–0.64) can be suppressed below inter-constitutional differences via multiple measurement protocols; whether non-Indian populations require independent reference baselines for tri-dosha frequencies.

    Related Reading

    Evidence Level: A
    References: PMID 30668163, PMID 30882597, PMID 18528411, PMID 32647148, PMID 32505705, PMID 33856258, PMID 20962650, PMID 22809539, PMID 37287336


    Disclaimer: This article compiles traditional knowledge and scientific literature for comparison and research-design discussion only. It is not medical advice and cannot replace professional diagnosis or treatment. Effect sizes, frequency ranges and exposure conclusions cited here are largely inferences at the research-report level, and individual circumstances vary widely. If you have any discomfort or health concerns, please consult a physician.